Search
Copper oxodotreotide Cu-64
go.drugbank.com/drugs/DB15873ApprovedCopper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over <sup>68</sup>Ga-labeled somatostatin analogs for positron emission tomography (PET). … Further, PET using Copper Cu 64 dotatate has been found to perform better than the current gold standard of single-photon emission computed tomography (SPECT) using 111In-DTPA-octreotide.
Ferrous bisglycinate
go.drugbank.com/drugs/DB11210ApprovedIt is found in foods for food enrichment or in supplements for the treatment of iron deficiency or iron deficiency anemia.
Mixtures: Folika-MG, SetonET-ECElranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationalElranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. … It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one
Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerSynonyms: IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN CD3E (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN)), HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE WITH IMMUNOGLOBULINLinvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalBy binding to both targets simultaneously, linvoseltamab redirects T cells toward myeloma cells, forming an immunological synapse that activates T-cell–mediated cytotoxicity. … marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T
Categories: Bispecific B Cell Maturation Antigen-directed CD3 T Cell EngagerSerplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalMost recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953] … It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries.
Astemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnIt was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Products: ALMIZOL 10 MG TABLET, 10 ADET, Hismanal Suspension 2mg/mlVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...
Rutin
go.drugbank.com/drugs/DB01698ApprovedInvestigationalA flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.
Mixtures: Nutriforte Non-Acidic Vitamin C 1000 mg with BioflavonoidsCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[A199122] This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. … Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades
Nicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnNicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. … Nevertheless, it is predominantly found paired with nonivamide as a combination topical analgesic product where its proposed mechanism of action as a rubefacient is complementary and ultimately synergistic
Mixtures: Nonivamid + Nicoboxil Zentiva 4 mg/g + 25 mg/g Salbe